相关实验视频

Updated: Jul 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

美国食品和药物管理局正在调查与CAR相关的T细胞恶性瘤

Cancer discovery

|November 30, 2023

概括

美国食品和药物管理局 (FDA) 正在调查血液癌症的CAR T细胞疗法潜在的二次癌症. 专家认为,这些免疫疗法的救生效益目前超过了这种罕见的风险.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

针对BCMA和CD19的化学抗原受体 (CAR) T细胞疗法是针对血液癌症的先进治疗方法.
这些免疫疗法已经证明了显著的疗效,挽救了许多人的生命.

研究的目的:

调查可能与BCMA和CD19导向的CAR T细胞免疫疗法相关的二次恶性瘤报告.
评估这些拯救生命的癌症治疗的风险益处概况.

主要方法:

美国食品和药物管理局正在积极监测和调查不良事件报告.
对患者结果和长期随访的数据分析正在进行中.

主要成果:

报告表明,CAR T细胞疗法与二次恶性瘤之间存在潜在的关联.
这些二次癌症的发病率和因果关系正在进行彻底的调查.

结论:

虽然存在潜在风险,但CAR T细胞疗法的已确定的救命益处被认为超过了当前的风险.
持续的监测和研究对于充分了解和减轻任何长期安全问题至关重要.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.